HTT and Huntington disease: In the recent status of HD drug therapies, only tetrabenazine is approved by Food and Drug Administration (FDA) to treat chorea and other HD-related motor symptoms by modulating dopamine receptors (Wang et al., 2010; de Tommaso et al., 2011; Kumar et al., 2020) Available therapeutics of HD mainly target Htt aggregation, transcriptional dysregulation, mitochondrial dysfunction, excitotoxicity via dopamine and glutamate pathways, caspase and stem cell transplants (Kumar et al., 2020).